Cargando…

Wnt Inhibitors and Bone Mineral Density in Patients with Graves’ Disease Treated with Antithyroid Drugs: A Preliminary Prospective Study

This study aimed to investigate the association of Wnt inhibitors with thyroid hormones, bone turnover markers, and bone mineral density (BMD) in patients with newly diagnosed Graves’ disease (GD) at the beginning of the antithyroid treatment and after a follow-up period of one year. The study inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mudri, Dunja, Kizivat, Tomislav, Mihaljević, Ivica, Bilić Ćurčić, Ines
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413978/ https://www.ncbi.nlm.nih.gov/pubmed/36005583 http://dx.doi.org/10.3390/metabo12080711

Ejemplares similares

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling
por: Mudri, Dunja, et al.
Publicado: (2023)

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
por: Kizivat, Tomislav, et al.
Publicado: (2020)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Canecki-Varžić, Silvija, et al.
Publicado: (2016)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019)

Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis
por: Kizivat, Tomislav, et al.
Publicado: (2017)

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
por: Omanovic Kolaric, Tea, et al.
Publicado: (2022)

Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
por: Bilic Curcic, Ines, et al.
Publicado: (2021)

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy
por: Mihaljević, Vjera, et al.
Publicado: (2022)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022)

Bone microarchitecture and bone mineral density in Graves’ disease
por: Boro, Hiya, et al.
Publicado: (2023)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease
por: Bošnjak, Ivica, et al.
Publicado: (2023)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study
por: Karmisholt, J., et al.
Publicado: (2019)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
por: Ninčević, Vjera, et al.
Publicado: (2022)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection—Induction of Autoimmune Dysregulation and Metabolic Disturbances
por: Grubišić, Barbara, et al.
Publicado: (2023)

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease
por: Gill, Harinder, et al.
Publicado: (2010)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs
por: Cheng, Ying, et al.
Publicado: (2020)

NONOBSTRUCTIVE CORONARY ARTERY DISEASE – CLINICAL RELEVANCE, DIAGNOSIS, MANAGEMENT AND PROPOSAL OF NEW PATHOPHYSIOLOGICAL CLASSIFICATION
por: Makarović, Zorin, et al.
Publicado: (2018)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
por: Bojanic, Kristina, et al.
Publicado: (2020)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

The Association of Severe Coronary Tortuosity and Non-Obstructive Coronary Artery Disease
por: Zebic Mihic, Petra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g6ijcdfsre8gsm4qbsrusd4503